Panoply™ Human IRAK4 Knockdown Stable Cell Line

Abnormal activation of NF-κB transcription factors is a fundamental cause of chemoresistance in various cancers, including colorectal cancer (CRC). Targeting its activation mechanisms, particularly using upstream IκB kinase (IKK) complex inhibitors, is a promising strategy to enhance chemotherapy efficacy. However, limited clinical efficacy has been observed due to the low specificity and high toxicity of the tested compounds. In solid tumors, IKK is primarily driven by Toll-like receptor (TLR)/IL-1 receptor family members, which signal through IL-1 receptor-associated kinases (IRAKs), with IRAK4 being the most critical subtype. The pathogenic role and therapeutic value of IRAK4 in colorectal cancer have not yet been investigated. Here, researchers found that inhibiting IRAK4 significantly suppressed colitis-induced tumorigenesis in APC^Min/+ mice, and bone marrow transplantation experiments demonstrated a crucial role for IRAK4 in immune cells during tumor progression. Chemotherapy significantly enhanced IRAK4 and NF-κB activity in colorectal cancer cells by upregulating TLR9 expression, and this activity could be inhibited by IRAK4 and IKK inhibitors, suggesting a positive feedback loop that protects colorectal cancer cells from chemotherapy-induced damage. Finally, elevated tumor phosphorylated IRAK4 staining or IRAK4 mRNA expression levels were significantly associated with shorter survival in colorectal cancer patients. These findings support targeting IRAK4 to improve chemotherapy efficacy and prognosis in colorectal cancer.

To investigate the causal relationship between IRAK4 and NF-κB activity, researchers constructed IRAK4-knockdown DLD-1 and KM12 colorectal cancer cell lines. In IRAK4-knockdown cells, the levels of p-IRAK1, p-IKKα/β, p-p50, p-65, and nuclear p65 were significantly reduced (Figure 1A and B). Re-expression of wild-type IKKβ or, more effectively, expression of an activated IKKβ mutant, restored NF-κB activity in IRAK4-knockdown cells, indicating that IRAK4 is an upstream regulator of NF-κB activity. Notably, IRAK4-knockdown colorectal cancer cells also exhibited defects in anchorage-independent growth and tumor formation (Figure 1C and D).

Figure 1. IRAK4 drives NF-κB activity in human CRC cells. (Li Q, et al., 2019)